Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Deloitte
QuintilesIMS
Teva
Medtronic
UBS
US Army
McKinsey
Healthtrust

Generated: January 19, 2019

DrugPatentWatch Database Preview

TAKEDA Company Profile

« Back to Dashboard

Summary for TAKEDA

Drugs and US Patents for TAKEDA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-004 Mar 27, 2012 DISCN No No 7,919,118 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-008 Mar 27, 2012 DISCN No No 7,084,245 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-001 Jan 30, 2009 RX Yes No 7,790,755*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-001 Jan 25, 2013 RX Yes No 7,078,381 ➤ Try a Free Trial ➤ Try a Free Trial
Takeda Pharms Usa TRINTELLIX vortioxetine hydrobromide TABLET;ORAL 204447-001 Sep 30, 2013 RX Yes No 8,476,279 ➤ Try a Free Trial Y ➤ Try a Free Trial
Takeda Pharms Usa DEXILANT dexlansoprazole CAPSULE, DELAYED RELEASE;ORAL 022287-002 Jan 30, 2009 AB RX Yes Yes 6,462,058*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for TAKEDA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842-001 Aug 29, 2005 6,166,042 ➤ Try a Free Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-004 Jan 25, 2013 6,150,384 ➤ Try a Free Trial
Takeda Pharms Usa ACTOS pioglitazone hydrochloride TABLET;ORAL 021073-001 Jul 15, 1999 6,303,640 ➤ Try a Free Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-003 Jan 25, 2013 6,211,205 ➤ Try a Free Trial
Takeda Pharms Usa OSENI alogliptin benzoate; pioglitazone hydrochloride TABLET;ORAL 022426-001 Jan 25, 2013 6,303,661 ➤ Try a Free Trial
Takeda Pharms Usa ACTOS pioglitazone hydrochloride TABLET;ORAL 021073-002 Jul 15, 1999 6,150,384 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for TAKEDA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Pellets/Capsul 15 mg and 30 mg ➤ Subscribe 2005-12-05
➤ Subscribe Capsule 60 mg ➤ Subscribe 2010-08-25
➤ Subscribe Extended-release Tablets 15 mg/1000 mg and 30 mg/1000 mg ➤ Subscribe 2011-09-23
➤ Subscribe Tablets 0.6 mg ➤ Subscribe 2011-12-23
➤ Subscribe Tablets 12.5 mg/500 mg and 12.5 mg/1000 mg ➤ Subscribe 2017-01-25
➤ Subscribe Tablets 8 mg ➤ Subscribe 2009-07-22
➤ Subscribe Tablets 40 mg and 80 mg ➤ Subscribe 2013-02-13
➤ Subscribe Delayed-release Orally Disinte 15 mg and 30 mg ➤ Subscribe 2006-12-27
➤ Subscribe Delayed-release Capsule 30 mg ➤ Subscribe 2010-11-30
➤ Subscribe Tablets 15 mg/500 mg and 15 mg/850 mg ➤ Subscribe 2008-03-06
➤ Subscribe Tablets 30 mg/2 mg and 30 mg/4 mg ➤ Subscribe 2009-12-22
➤ Subscribe Tablets 6.25 mg, 12.5 mg and 25 mg ➤ Subscribe 2017-01-25
➤ Subscribe Tablets 5 mg, 10 mg, 15 mgand 20 mg ➤ Subscribe 2017-10-02

Supplementary Protection Certificates for TAKEDA Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
374 Luxembourg ➤ Try a Free Trial PRODUCT NAME: ALOGLIPTIN SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE. FIRST REGISTRATION: 20130923
2014011 Lithuania ➤ Try a Free Trial PRODUCT NAME: ALOGLIPTINUM; REGISTRATION NO/DATE: EU/1/13/844 20130919
C015/2010 Ireland ➤ Try a Free Trial SPC015/2010: 20101001, EXPIRES: 20230420
00357 Netherlands ➤ Try a Free Trial PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
C0022 France ➤ Try a Free Trial PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421
2014026 Lithuania ➤ Try a Free Trial PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fuji
Farmers Insurance
Johnson and Johnson
Cantor Fitzgerald
Moodys
Daiichi Sankyo
Argus Health
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.